-- CSPC Pharmaceutical (HKG:1093) obtained clinical trial approval for SYS6051 from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
The indication for the approval is advanced solid tumors. Preclinical studies demonstrated good anti-tumor effects on a variety of cancers.